SCHEMBL342176

SCHEMBL342176

CCCCCCCCCCCCCOc1ccccc1C(=O)O

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.74
MEN1 O00255 2/20 0.74
LMNA P02545 2/20 0.74
CYP3A4 P08684 2/20 0.74
NR1I2 O75469 1/20 0.74
CHRM2 P08172 1/20 0.74
ADRA2A P08913 1/20 0.74
MAPT P10636 1/20 0.74
OPRK1 P41145 1/20 0.74
HTR2B P41595 1/20 0.74
SLC6A3 Q01959 1/20 0.74
HDAC6 Q9UBN7 1/20 0.74
PTPN11 Q06124 6/20 0.68
ALDH1A1 P00352 4/20 0.65
PTK2B Q14289 1/20 0.65
NPSR1 Q6W5P4 1/20 0.62
KDM4E B2RXH2 1/20 0.60
RECQL P46063 1/20 0.60
PTPN1 P18031 3/20 0.60
S1PR3 Q99500 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2044840 1.00 KMT2A (0.74) KMT2AMEN1LMNACYP3A4NR1I2
SCHEMBL18140779 1.00 KMT2A (0.74) KMT2AMEN1LMNACYP3A4NR1I2
SCHEMBL18141371 1.00 KMT2A (0.74) KMT2AMEN1LMNACYP3A4NR1I2
SCHEMBL3665313 1.00 KMT2A (0.74) KMT2AMEN1LMNACYP3A4NR1I2
SCHEMBL1274781 1.00 KMT2A (0.74) KMT2AMEN1LMNACYP3A4NR1I2
SCHEMBL527254 1.00 KMT2A (0.74) KMT2AMEN1LMNACYP3A4NR1I2
SCHEMBL6575990 1.00 KMT2A (0.74) KMT2AMEN1LMNACYP3A4NR1I2
SCHEMBL168816 1.00 KMT2A (0.74) KMT2AMEN1LMNACYP3A4NR1I2
SCHEMBL112985 1.00 KMT2A (0.74) KMT2AMEN1LMNACYP3A4NR1I2
SCHEMBL1005992 1.00 KMT2A (0.74) KMT2AMEN1LMNACYP3A4NR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 312 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025133227-A1 ANTI-GREY HAIR CARE COMPOSITIONS UNILEVER IP HOLDINGS B.V. (NL) 2025-06-26 WO claimed
EP-1933807-B1 COSMETIC PRODUCT FOR THE TREATMENT OF SCALP CUTRIN OY (FI) 2015-11-04 EP claimed
EP-1176949-B1 LIPID PARTICLES ON THE BASIS OF MIXTURES OF LIQUID AND SOLID LIPIDS AND METHOD FOR PRODUCING SAME PHARMASOL GMBH (DE) 2014-12-10 EP claimed
US-20120321685-A1 COMPOSITIONS CONTAINING OILS HAVING A SPECIFIC GRAVITY HIGHER THAN THE SPECIFIC GRAVITY OF WATER SOL-GEL TECHNOLOGIES LTD. (IL) 2012-12-20 US claimed
EP-2324812-A2 Composition exhibiting enhanced formulation stability and delivery of topical active ingredients Sol-Gel Technologies Ltd. (IL) 2011-05-25 EP claimed
US-20050037087-A1 Compositions containing oils having a specific gravity higher than the specific gravity of water SOL-GEL TECHNOLOGIES LTD. (IL) 2005-02-17 US claimed
EP-1446086-A1 COMPOSITIONS CONTAINING OILS HAVING A SPECIFIC GRAVITY HIGHER THAN THE SPECIFIC GRAVITY OF WATER Sol-Gel Technologies Ltd. (IL) 2004-08-18 EP claimed
JP-2003534249-A 2003-11-18 JP claimed
EP-1335693-A2 COMPOSITION EXHIBITING ENHANCED FORMULATION STABILITY AND DELIVERY OF TOPICAL ACTIVE INGREDIENTS Sol-Gel Technologies Ltd. (IL) 2003-08-20 EP claimed
WO-2003039510-A1 COMPOSITIONS CONTAINING OILS HAVING A SPECIFIC GRAVITY HIGHER THAN THE SPECIFIC GRAVITY OF WATER SOL-GEL TECHNOLOGIES LTD. (IL) 2003-05-15 WO claimed
WO-2003034979-A2 COMPOSITION EXHIBITING ENHANCED FORMULATION STABILITY AND DELIVERY OF TOPICAL ACTIVE INGREDIENTS SOL-GEL TECHNOLOGIES LTD. (IL) 2003-05-01 WO claimed
EP-0987011-B1 Cosmetic and/or dermatological composition containing salicylic acid or its derivatives and its use OREAL (FR) 2002-07-17 EP claimed
EP-0886517-B1 METHOD FOR REDUCING SKIN OILS AND GREASE UNILEVER PLC (GB) 2002-07-03 EP claimed
US-20020064541-A1 Composition exhibiting enhanced formulation stability and delivery of topical active ingredients SOL-GEL TECHNOLOGIES LTD. (IL) 2002-05-30 US claimed
EP-0881896-B1 SKIN TREATMENT WITH SALICYLIC ACID ESTERS AND RETINOIDS FD MAN INC (US) 2002-05-02 EP claimed
EP-1176949-A2 LIPID PARTICLES ON THE BASIS OF MIXTURES OF LIQUID AND SOLID LIPIDS AND METHOD FOR PRODUCING SAME Pharmasol GmbH (DE) 2002-02-06 EP claimed
WO-2001080823-A2 COMPOSITION EXHIBITING ENHANCED FORMULATION STABILITY AND DELIVERY OF TROPICAL ACTIVE INGREDIENTS SOL-GEL TECHNOLOGIES LTD. (IL) 2001-11-01 WO claimed
WO-2000067728-A2 LIPID PARTICLES ON THE BASIS OF MIXTURES OF LIQUID AND SOLID LIPIDS AND METHOD FOR PRODUCING SAME PHARMASOL GMBH (DE) 2000-11-16 WO claimed
WO-2026047058-A1 COMPOSITION AND METHOD FOR PERSONALISED BENEFITS UNILEVER IP HOLDINGS B.V. (NL) 2026-03-05 WO disclosed
EP-0239444-A1 Ferroelectric liquid crystal, process for its manufacture and its use in a liquid-crystal mixture THOMSON-CSF (FR) 1987-09-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120321685-A1 COMPOSITIONS CONTAINING OILS HAVING A SPECIFIC GRAVITY HIGHER THAN THE SPECIFIC GRAVITY OF WATER GNG2, COG5, SQLE KMT2A 4023/4885MEN1 176/4885LMNA 2814/4885
US-20050037087-A1 Compositions containing oils having a specific gravity higher than the specific gravity of water GNG2, COG5, SQLE KMT2A 4023/4885MEN1 176/4885LMNA 2814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.